Hercules Technology Growth Capital (HTGC)
$11.19 0.06 (0.54%)
16:42 EDT HTGC Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 975.84M
PE Ratio 10.27
Volume (Avg. Vol.) 922,472
Day's Range 11.01 - 11.24
52-Week Range 5.42 - 16.40
Dividend & Yield 1.26 (11.26%)
HTGC Stock Predictions, Articles, and Hercules Technology Growth Capital News
- From InvestorPlace
- From the Web
Investors don't need a crystal ball to see how major trends in sectors such as e-commerce and biotech are supporting the best stocks in 2020.
Hercules Capital will continue to be one of the best stocks to buy thanks to its corporate structure and generous dividend.
SPACs are soaking up attention, but they come with too much risk and not enough disclosure. Here are two better ways to play the space.
Some of the best tech stocks to buy are lesser known companies leading key innovations. Here are six oddballs many investors are overlooking.
As economic uncertainty lingers, look for value stocks that have excellent long-term narratives. Here are five picks to get started now.
How will InvestorPlace.com's Best Stocks for 2020 contest end? Your guess is as good as mine, but Q3 will be an interesting one to watch.
Hercules Capital isn't winning the Best Stocks contest right now, but HTGC stock is still a cheap buy after returning 41.5% in Q2.
There's nothing "artificial" about these AI stocks to buy now. Each represents cutting-edge technology, and offers solid income along the way.
The best dividend stocks combine price appreciation and a yield that boosts your earnings in good times and cushions them in bad ones.
InvestorPlace's Best Stocks for 2020 contest looks dismal after Q1. What will happen with the pandemic, and which stock will win?
Hercules Capital represents forward-looking tech trends that are thriving right now. This makes HTGC stock a steal at its discounted price.
Bank stocks are lagging the market, stunted by regulations in the wake of the financial crisis. But these alt-financials are great buys.
These dividend stocks offer surprising ways to earn reliable income. From trash companies to agricultural chemicals, check these stocks out.
Which of our experts will win the best stocks contest? They're all betting on themes likely to dominate in 2020 and beyond.
Hercules Capital is one of the best stocks because it will rally through November 2020 and pays out cash in a big way for shareholders.
If you're looking to boost the income potential of your portfolio, these less-known dividend stocks may be just what you're looking for.
From Seeking Alpha
Geron (NASDAQ:GERN) enters into a loan facility for up to $75M with Hercules Capital (NYSE:HTGC) and Silicon Valley Bank, available in three tranches through 2022.The facility will be used to support the company's imetelstat development program, working capital and general corporate purposes."This debt financing strengthens our balance sheet and provides additional financial flexibility as our imetelstat program advances with two Phase 3 registration-enabling clinical trials – the ongoing IMerge trial in lower risk myelodysplastic syndromes and the planned trial in refractory myelofibrosis," says CFO Olivia K.
From Seeking Alpha
Bicycle Therapeutics (NASDAQ:BCYC) completed its at-the-market offering program initiated during Q3 generating gross proceeds of $50M.Also, it closed a financing with Hercules Capital (NYSE:HTGC) for a term loan of up to $40M in two tranches; an initial tranche of $30M will be fully available at the loan closing, with a minimum draw of $15M.Financings will allow the company to continue progressing its three clinical programs, support clinical development of lead immuno-oncology candidate BT7480, expected to commence in 2021; extend cash runway well into the 1H23."Over the course of 2020, we have continued to execute on our financing strategy, generating approximately $120M, over half of which was non-dilutive and the remainder was pursuant to our ATM program," president & CFO Lee Kalowski commented.
The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut
Navellier RatingsPowered by Portfolio Grader